Bank of Montreal Can Acquires 444,084 Shares of Catalent, Inc. (NYSE:CTLT)

Bank of Montreal Can grew its stake in shares of Catalent, Inc. (NYSE:CTLT) by 222.0% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 644,123 shares of the company’s stock after purchasing an additional 444,084 shares during the period. Bank of Montreal Can owned about 0.36% of Catalent worth $36,219,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Lindbrook Capital LLC boosted its position in shares of Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after buying an additional 208 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Catalent during the 2nd quarter worth $42,000. Mather Group LLC. bought a new stake in shares of Catalent in the 1st quarter worth $52,000. Longfellow Investment Management Co. LLC raised its holdings in shares of Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares in the last quarter.

Catalent Stock Performance

NYSE:CTLT opened at $60.29 on Friday. The company has a market capitalization of $10.91 billion, a P/E ratio of -9.88, a P/E/G ratio of 2.32 and a beta of 1.15. The business has a fifty day simple moving average of $59.64 and a two-hundred day simple moving average of $57.31. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96. Catalent, Inc. has a 1 year low of $31.80 and a 1 year high of $61.20.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.13. The company had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.23 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. On average, analysts expect that Catalent, Inc. will post 0.85 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on CTLT. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. StockNews.com began coverage on Catalent in a research report on Thursday. They issued a “sell” rating on the stock. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Robert W. Baird reissued a “neutral” rating and issued a $63.50 price target on shares of Catalent in a report on Tuesday. One equities research analyst has rated the stock with a sell rating and eight have given a hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $59.83.

Insider Transactions at Catalent

In related news, insider Ricky Hopson sold 662 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the sale, the insider now directly owns 29,974 shares in the company, valued at approximately $1,785,251.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the sale, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Ricky Hopson sold 662 shares of the stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the sale, the insider now directly owns 29,974 shares in the company, valued at $1,785,251.44. The disclosure for this sale can be found here. Insiders sold 13,409 shares of company stock worth $782,923 over the last quarter. Corporate insiders own 0.31% of the company’s stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.